Sources and small print
* Results are based on the STEP 1 Wegovy trial and SURMOUNT-1 Mounjaro trial, in which participants lost an average of 15% and 21% of their starting weight, respectively. Results vary – weight loss can be more or less than the average.
Wilding, J.P.H. et al. (2021) "Once-weekly semaglutide in adults with overweight or obesity" New England Journal of Medicine, 384(11)
https://doi.org/10.1056/NEJMoa2032183
Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" New England Journal of Medicine, 387(3)
https://doi.org/10.1056/NEJMoa2206038
** An admin fee may apply for early cancellation. See our terms and conditions.
*** Terms and conditions apply.
Contact Details
17 D-F Telford Court, Chestergates Business Park, Chester, United Kingdom, CH1 6LT.
Quick Links
Guides
We only offer our programme in the UK and Northern Ireland. We are currently unable to deliver to the Republic of Ireland.
All Rights Reserved | SemaPen Ltd. | Digital marketing from My Digital Hero